OriV508
/ Oricell
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 10, 2025
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
August 05, 2025
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology
New P1 trial • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
1 to 2
Of
2
Go to page
1